Product Information
LUIZZA 1.5 MG-30 MCG TABLET is a generic product labeled by Xiromed LLC, priced at $0.3358 per EA under NDC 70700031479. Its NADAC has been published 49 times since Oct 29, 2025.
FDA first approved this application on Feb 19, 2015. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
30; 1.5 ug/1; mg/1
Manufacturer
Xiromed LLCNDC
70700031479
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ETHINYL ESTRADIOL; NORETHINDRONE ACETATEApproval Type
Generic (ANDA)
FDA Application
ANDA202770FDA Approved
2/19/2015
TE Code
AB
On Market Since
1/29/2025
Price Statistics
The NADAC for LUIZZA 1.5 MG-30 MCG TABLET has been published 49 times since Oct 29, 2025, and over the history we have for it it has declined 12.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3358 per EA |
|---|---|
| All-time high | $0.3923 (Dec 10, 2025) |
| All-time low | $0.3344 (Mar 18, 2026) |
| 52-week high | $0.3923 |
| 52-week low | $0.3344 |
| Median price | $0.3486 |
| Average price | $0.3585 |
| Largest weekly change | -7.8% (Feb 18, 2026) |
| Weeks tracked | 49 |
| Tracking since | Oct 29, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the norethindrone acetate and ethinyl estradiol market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Xiromed LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
norethindrone acetate and ethinyl estradiol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Estrogen class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LUIZZA 1.5 MG-30 MCG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LUIZZA 1.5 MG-30 MCG TABLET, manufactured by Xiromed LLC, is $0.3358 per EA (NDC 70700031479), effective Sep 30, 2026.
How has the price of LUIZZA 1.5 MG-30 MCG TABLET changed over time?
Over the history we have for it, the NADAC for LUIZZA 1.5 MG-30 MCG TABLET has declined 12.4%. It has been tracked across 49 weekly CMS publications since Oct 29, 2025.
What are the highest and lowest recorded NADAC prices for LUIZZA 1.5 MG-30 MCG TABLET?
Since Oct 29, 2025, the NADAC for LUIZZA 1.5 MG-30 MCG TABLET has ranged from a low of $0.3344 (Mar 18, 2026) to a high of $0.3923 (Dec 10, 2025), with a median of $0.3486 per EA.
Are there cheaper alternatives to LUIZZA 1.5 MG-30 MCG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of LUIZZA 1.5 MG-30 MCG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures LUIZZA 1.5 MG-30 MCG TABLET?
LUIZZA 1.5 MG-30 MCG TABLET (NDC 70700031479) is labeled by Xiromed LLC, and CMS classifies it as a generic product.